Underlying EBITDA margin at 30.1% in line with revenue; focused cost management
No significant impact from destocking expected for H2; outlook 2023 confirmed
Announced acquisition of Polyplus: further broadening of portfolio for Advanced Therapies
2
Agenda
Sartorius Group
Q1 2023 results | FY 2023 guidance
Sartorius Stedim Biotech Group
Q1 2023 results | FY 2023 guidance
Questions & Answers
3
Sartorius Group
Ongoing demand normalization as expected
Sartorius Group
Q1 2022
Q1 2023
in %
in % cc1
in millions of € unless otherwise specified
Sales revenue
1,025
903
-11.9
-13.2
Order intake
1,112
765
-31.2
-32.0
Underlying EBITDA2
349
272
-22.1
Underlying EBITDA2 margin in %
34.1
30.1
-3.9pp
Underlying EPS3 (ord.) in €
2.44
1.69
-30.6
Underlying EPS3 (pref.) in €
2.45
1.70
-30.5
Marginal Covid-related business; excluding this effect, sales decline in the mid single-digit percentage range
OI strongly affected by customer destocking; normalization effect expected to fade in H2 2023
Underlying EBITDA margin below prior year as a result of sales development and a higher cost base
Q1 2022 figures restated due to final PPA for the acquisitions of ALS Automated Lab Solutions and the Novasep Chromatography Division 1 Constant currencies 2 Underlying = excluding extraordinary items 3 Underlying EPS = based on net profit after non-controlling interest; adjusted for extraordinary items as well as amortization and based on a normalized financial result and normalized tax rate
4
Sartorius Group
Navigating through volatility: Temporary decline in perspective
vs. Q1 19
vs. Q1 20
Sales revenue
+105%
+76%
Order intake
+57%
+21%
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
2019
2020
2021
2022
2023
Sales ex Covid
Covid-19-related sales
Order intake
5
Attachments
Original Link
Original Document
Permalink
Disclaimer
Sartorius Stedim Biotech SA published this content on 20 April 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 April 2023 14:24:08 UTC.
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically.
For next generation processes, Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of turning science into solutions on a daily basis.
With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany.
SARTORIUS STEDIM BIOTECH 
